A major focus of his laboratory is new drug development, for which his Center has received NIH funding. Within the Center is a dedicated phase I facility, where first-in-human and early phase studies are conducted. His Center has worked closely with private industry to develop new antiplatelet agents, and has played a pivotal role in the development of two recently approved antiplatelet agents (prasugrel and ticagrelor) indicated for the treatment of ACS. Dr. Gurbel's current research is focused on further understanding how genotype and various aspects of platelet function should be used to optimally identify the patient with high cardiovascular risk.